Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis-Reference-Cited by-同舟云学术

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Published:2014-10-16 Issue:16 Volume:124 Page:2507-2513
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Tefferi Ayalew¹,Guglielmelli Paola²,Larson Dirk R.³,Finke Christy¹,Wassie Emnet A.¹,Pieri Lisa²,Gangat Naseema¹,Fjerza Rajmonda²,Belachew Alem A.¹,Lasho Terra L.¹,Ketterling Rhett P.⁴,Hanson Curtis A.⁵,Rambaldi Alessandro⁶,Finazzi Guido⁶,Thiele Juergen⁷,Barbui Tiziano⁶,Pardanani Animesh¹,Vannucchi Alessandro M.²

Affiliation:

1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;

2. Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;

3. Department of Statistics and Bioinformatics,

4. Division of Cytogenetics, Department of Laboratory Medicine, and

5. Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN;

6. Division of Hematology and Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and

7. Institute of Pathology, University of Cologne, Cologne, Germany

Abstract

Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/16/2507/1380193/2507.pdf

Reference22 articles.

1. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.;Tefferi;J Clin Oncol,2011

2. Somatic mutations of calreticulin in myeloproliferative neoplasms.;Klampfl;N Engl J Med,2013

3. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.;Nangalia;N Engl J Med,2013

4. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.;Rotunno;Blood,2014

5. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.;Rumi;Blood,2014

Cited by 555 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms;Scientific Reports;2024-02-02

2. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02

3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25

4. One thousand patients with essential thrombocythemia: the Mayo Clinic experience;Blood Cancer Journal;2024-01-18

5. COMPARISON OF PATIENTS WITH PRE-DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH LOW AND HIGH JAK2V617F ALLELE BURDEN IN TERMS OF CLINICAL AND HEMATOLOGICAL PARAMETERS;Kocatepe Tıp Dergisi;2024-01-17